Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
Authors: GomezMancilla B; Novartis Institutes for BioMedical Research, Basel, Switzerland., Meriggioli MN; Novartis Biomedical Research, Cambridge, MA, USA. Electronic address: matthew.meriggioli@novartis.com., Genge A; Montreal Neurological Institute and Hospital, Montreal, Canada., Roubenoff R; Novartis Institutes for BioMedical Research, Basel, Switzerland., Espié P; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dupuy C; Novartis Institutes for BioMedical Research, Basel, Switzerland., Hartmann N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Pezous N; Novartis Institutes for BioMedical Research, Basel, Switzerland., Kinhikar A; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Tichy M; Novartis Institutes for BioMedical Research, Basel, Switzerland., Dionne A; CHU de Quebec Universite Laval, Quebec, Canada., Vissing J; Rigshospitalet, University of Copenhagen, Denmark., Andersen H; Aarhus University Hospital, Aarhus, Denmark., Schoser B; Friedrich-Baur-Institute, Dep. of Neurology, LMU Klinikum Muenchen, Muenchen, Germany., Meisel A; Charité Universitätsmedizin Berlin, Department of Neurology, Germany., Jordan B; Department of Neurology, University Hospital of Halle, Halle, Germany; epartment of Neurology, University Hospital of Heidelberg, Heidelberg, Germany., Devlikamova F; Republican Clinical Hospital of Medical Rehabilitation, Kazan, Russia., Poverennova I; Samara Regional Clinical Hospital named after M.I.Kalinin, Samara, Russia., Stuchevskaya F; City Multi-specialty Hospital, St. Petersburg, Russia., Lin TS; National Cheng Kung University Hospital, Tainan, Taiwan., Rush JS; Novartis Institutes for BioMedical Research, Basel, Switzerland; Kling Biotherapeuetics BV, Amsterdam, the Netherlands., Gergely P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
Source: Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia [J Clin Neurosci] 2024 Jan; Vol. 119, pp. 76-84. Date of Electronic Publication: 2023 Nov 20.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Churchill Livingstone Country of Publication: Scotland NLM ID: 9433352 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-2653 (Electronic) Linking ISSN: 09675868 NLM ISO Abbreviation: J Clin Neurosci Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1532-2653
DOI:10.1016/j.jocn.2023.11.013